PMID: 11919239Mar 29, 2002Paper

Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Marko B Lens, Martin Dawes

Abstract

No standard systemic adjuvant therapy has been proven to increase overall survival in melanoma patients. The effect of interferon alfa (IFNalpha) as a single agent or in combination has been widely explored in clinical trials. The purpose of this study was to assess the benefit of IFNalpha therapy in malignant melanoma. We performed a systematic review of randomized controlled trials comparing regimens with or without IFNalpha adjuvant therapy in melanoma patients. We assessed the effect of IFNalpha therapy on overall survival (OS), disease-free survival (DFS), melanoma recurrences, and toxicity. The quality of each trial was systematically evaluated. Nine randomized controlled trials (RCTs) of IFNalpha therapy in melanoma patients were identified. Eight were published and one was unpublished. Eight trials comprising 3,178 patients fulfilled our inclusion criteria and were analyzed. Quality assessment scores ranged from 22 to 71, with a mean score of 55.4 (95% confidence interval, 53.8 to 57.0). For OS, only one trial reported a statistically significant benefit for IFNalpha, but our analysis did not confirm it. Two trials reported statistically significant benefit in DFS for the patients treated with IFNalpha, but our analysis...Continue Reading

References

Apr 1, 1992·Archives of Surgery·D L MortonA J Cochran
Oct 1, 1989·Urology·R J Spiegel
Apr 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M Kirkwood, M S Ernstoff
Nov 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E T CreaganL J Rodrigue
May 1, 1995·Journal of the American Academy of Dermatology·T M JohnsonA Chang
Jan 15, 1995·Cancer·A Barth, D L Morton
Jan 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M KirkwoodR H Blum
Oct 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B F ColeE Borden
Mar 1, 1997·Archives of Dermatology·J Cook, J A Zitelli
Mar 1, 1997·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·R M McKenna, K E Oberg
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H PehambergerK Wolff
Jul 21, 1998·Seminars in Cutaneous Medicine and Surgery·I H Olhoffer, J L Bolognia
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J M Kirkwood
Apr 22, 2000·Cancer Treatment Reviews·B W HancockM Gore
Jun 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M KirkwoodR H Blum
Jun 17, 2000·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·A M Eggermont
Sep 27, 2000·Journal of the American Academy of Dermatology·A Kimyai-Asadi, A Usman
Oct 24, 2000·Clinical and Experimental Dermatology·S Whittaker
May 31, 2001·British Journal of Cancer·D A CameronUNKNOWN Scottish Melanoma Group

❮ Previous
Next ❯

Citations

Sep 5, 2002·Cancer·Vernon K Sondak
Aug 24, 2006·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·A Hauschild, U R Kleeberg
Jun 1, 2010·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·K C KählerA Hauschild
Jan 26, 2005·Cancer Immunology, Immunotherapy : CII·Gregory B LesinskiWilliam E Carson
May 11, 2010·Cancer Immunology, Immunotherapy : CII·Malcolm S MitchellTheresa L Whiteside
Oct 26, 2005·International Journal of Clinical Oncology·Arata TsutsumidaTsuneki Sugihara
Apr 19, 2005·Biomedical Microdevices·Gregory B LesinskiWilliam E Carson
Jul 21, 2004·Clinics in Dermatology·Ken K LeeNeil A Swanson
Feb 22, 2003·Journal of the American College of Surgeons·Kelli M BullardMichael P Spencer
May 1, 2006·Clinics in Colon and Rectal Surgery·Marc Singer, Matthew G Mutch
Feb 20, 2004·The New England Journal of Medicine·J Meirion ThomasUNKNOWN Scottish Cancer Therapy Network
Sep 3, 2004·The New England Journal of Medicine·Hensin TsaoArthur J Sober
Jun 23, 2009·Cancer Biotherapy & Radiopharmaceuticals·Nuria AlvarezCristina Martínez
Jul 28, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A M M EggermontA Hauschild
Sep 26, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D SchadendorfL Zimmer
Sep 2, 2004·Journal of the National Cancer Institute·Gregory B LesinskiWilliam E Carson
Sep 25, 2003·Plastic and Reconstructive Surgery·Salvatore J PacellaRiley Rees
Jun 17, 2010·Journal of Immunotherapy·Doru T AlexandrescuConstantin A Dasanu
Jul 11, 2007·The Cancer Journal·Gaurav D Shah, Paul B Chapman
Mar 29, 2012·The Cancer Journal·Diwakar DavarJohn M Kirkwood
Oct 1, 2004·ANZ Journal of Surgery·Jarad M MartinLester J Peters
Aug 3, 2011·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·Sherrif F IbrahimDésirée Ratner
Nov 19, 2004·The British Journal of Ophthalmology·P N TulleyG D Wilson
Jan 6, 2012·Journal of Skin Cancer·Diwakar DavarJohn M Kirkwood
May 3, 2012·Radiology Research and Practice·Ximena Wortsman
Dec 18, 2004·Dermatology : International Journal for Clinical and Investigative Dermatology·R DummerUNKNOWN Task Force Skin Cancer
Oct 27, 2007·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Josep Domingo-DomènechRafael Molina
Oct 29, 2008·Journal of Translational Medicine·Paolo A Ascierto, John M Kirkwood
Feb 8, 2011·Radiation Oncology·Jean-Emmanuel BibaultEric Lartigau
Nov 8, 2007·Annals of Surgical Oncology·Carlo Riccardo RossiDonato Nitti
Sep 13, 2008·Annals of Surgical Oncology·Lynn DengelCraig L Slingluff
Aug 28, 2002·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Marios DecatrisKen O'Byrne
Jun 7, 2005·Expert Opinion on Emerging Drugs·Jean-Claude Bystryn, Jennifer L Rudolph
Jun 2, 2014·Hematology/oncology Clinics of North America·Vikram C Gorantla, John M Kirkwood
Apr 24, 2013·Clinics in Dermatology·Diwakar DavarJohn M Kirkwood
Jun 28, 2011·Annales de dermatologie et de vénéréologie·Serge Boulinguez, Florent Grange
Oct 28, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Katharina C KaehlerAxel Hauschild
Sep 18, 2002·Mayo Clinic Proceedings·Stephan D ThoméMichael P Heldebrant
Sep 9, 2008·International Journal of Radiation Oncology, Biology, Physics·Beth M BeadleGunar K Zagars
May 20, 2008·Surgical Oncology Clinics of North America·Alexander M M Eggermont, Christiane Voit
Apr 25, 2006·Surgical Oncology Clinics of North America·Alexander M M Eggermont

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.